Fluidigm Corp
Change company Symbol lookup
Select an option...
FLDM Fluidigm Corp
PFE Pfizer Inc
AGNC Agnc Investment Corp
AAPL Apple Inc
GRTYA Guaranty Corp
SATS EchoStar Corp
$DJI Dow Jones Industrials
TIKK Tel-Instrument Electronics Corp
TEAM Atlassian Corporation PLC
PAYX Paychex Inc
Go

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Postmarket

Last Trade
Delayed
$6.20
0.055 (0.90%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$6.15
Day's Change
0.085 (1.40%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
6.29
Day's Low
5.99
Volume
(Light)
Volume:
1,123,697

10-day average volume:
1,954,484
1,123,697

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fluidigm Corporation - FLDM

8:39 pm ET October 26, 2020 (Globe Newswire) Print

Pomerantz LLP is investigating claims on behalf of investors of Fluidigm Corporation ("Fluidigm" or the "Company") (NASDAQ: FLDM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Fluidigm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On August 1, 2019, Fluidigm reported second quarter 2019 revenues of $28.2 million, well below analysts' expectations of $32 million, citing weakness in the Company's microfluidics segment. On this news, Fluidigm's stock price fell $4.10 per share, or 34%, to close at $8.05 per share on August 2, 2019.

Then, on November 5, 2019, Fluidigm reported that its third quarter 2019 revenue had declined 8.5% year-over-year. On this news, Fluidigm's stock price fell $2.60 per share, or 51%, to close at $2.51 per share on November 6, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980

__GNW8366DE3E__IMG

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.